Compare MINISO Group Holding Ltd (MNSO) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MINISO Group Holding Ltd vs Neurocrine Biosciences Inc — how do they compare? MINISO Group Holding Ltd trades at $12.46 (market cap $3.87B), while Neurocrine Biosciences Inc trades at $179.88 (market cap $17.40B). The key difference: Neurocrine Biosciences Inc is far larger — about 4.5× MINISO Group Holding Ltd's market cap, and MINISO Group Holding Ltd pays a 5.21% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| MNSO | NBIX | |
|---|---|---|
Market Cap | $3.87B | $17.40B |
Sector | Technology | Health |
52-Week High | $26.63 | $180.55 |
52-Week Low | $11.30 | $123.10 |
Enterprise Value | $4.54B | $16.49B |
Dividend Yield | 5.21% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MNSO trades at $12.79, up 0.31% today, with a bullish technical signal driven by moving averages. The stock shows strong fundamentals with a P/E of 12.98 and net income margin of 8.98% for 2026. Recent Q1 2026 earnings beat expectations with EPS of $0.591, and the company announced a HK$2 billion share repurchase program on June 29, 2026, signaling confidence.
Outlook is positive given earnings momentum and valuation support, but risks include margin pressure from overseas expansion costs and mixed quarterly performance. Analyst consensus is 75% buy, though one sell rating highlights growth execution concerns. The stock remains a growth play with manageable valuation risks.
Neurocrine Biosciences (NBIX) trades at $173.00, up 1.24% with strong bullish momentum. Recent earnings beats, including Q1 2026 EPS of $1.94 versus $1.22 expected, underscore robust growth. The stock shows bullish technical signals with support at $170 and resistance at $173. Revenue growth accelerated to $2.86 billion in 2025, with net income margin improving to 21.55% in 2026 projections. Positive news highlights pipeline advancements and the Soleno acquisition.
Outlook remains positive with a consensus price target of $196.08, implying 13% upside. Key opportunities include sustained earnings growth and pipeline expansion, while risks involve clinical trial outcomes and competitive pressures. Institutional sentiment is strongly bullish with 86% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MINISO Group Holding Ltd
MINISO Group Holding Ltd is a global lifestyle product retailer known for its aesthetically pleasing, high-quality, and low-cost goods. The company operates a network of branded stores worldwide, offering a diverse range of merchandise, including household goods, cosmetics, toys, and digital accessories. MINISO's business model emphasizes rapid product iteration, efficient supply chain management, and a joint venture and franchise partner network to facilitate its global expansion.
Read more on MNSO →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
